Washington, April 27: A novel apparatus that resembles a human vein might be useful for blood clot research and could replace the use of animals in some tests.
MyJournals.org - Science - IJMS, Vol. 24, Pages 7683: Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19 (International Journal of Molecular Sciences)
/PRNewswire/ Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term.
FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection Paris and Stockholm – February 23, 2023 – The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-V.
Investegate announcements from Sanofi - Aventis Groupe, Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection